CDA and non-small cell lung carcinoma: This multicenter study evaluated the impact of CDA enzymatic activity on outcomes of advanced NSCLC patients treated with first-line platinum–gemcitabine regimens and prospectively validated the prognostic role of CDA activity as independent prognostic biomarker of activity and efficacy in these patients.